Hims & Hers Health Q2 Earnings Call Highlights
MarketBeat
Tue, August 11, 2026 at 8:33 AM GMT+5:30
7 min read
- HIMS
+0.57%
Key Points
Interested in Hims & Hers Health, Inc.? Here are five stocks we like better
Strong growth led by weight loss and international expansion: Q2 revenue rose nearly 40% year over year to more than $753 million, supported by 300,000 new subscribers and the Eucalyptus acquisition. Hims & Hers raised its 2026 revenue outlook to $3.1 billion–$3.3 billion
AI investment is improving engagement and efficiency: The company’s AI-enabled care experience tripled customer messaging, answered 80% of questions and reduced non-clinical support work by nearly 50%. Management expects these investments to generate returns within 12–18 months
Profitability faces near-term pressure: Adjusted EBITDA was $60 million, while adjusted gross margin fell to 64% and free cash flow was negative $68 million due to branded weight-loss expansion and working-capital needs. Management expects free cash flow to turn positive in the second half and projects Q3 revenue of $880 million–$900 million
The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally
Chief Financial Officer Yemi Okupe said domestic revenue rose 16% year over year to $622 million, while international revenue increased more than 17-fold to $131 million. The company’s June acquisition of Eucalyptus contributed about $40 million of second-quarter revenue
→ MarketBeat Week in Review – 08/03 – 08/07
Bearish Pressure Is Building Around These 3 Stocks
The results reflected stronger demand for expanded branded weight-loss offerings, as well as growth across newer categories and overseas markets. Hims & Hers raised its full-year revenue outlook to a range of $3.1 billion to $3.3 billion, representing projected growth of 32% to 41%
Weight Loss, Subscriber Growth Drive Results
Okupe said the company’s decision in March to broaden its branded weight-loss assortment helped reaccelerate growth in the second quarter. While a shift to monthly billing for branded weight-loss products created revenue-recognition headwinds, increased subscriber additions more than offset that effect, he said
→ Quantum Earnings Week: Winners and Losers Are Finally Emerging
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
Chief Executive Officer Andrew Dudum said Hims & Hers’ relationship with Novo Nordisk has helped expand access to weight-loss treatments. He described the launch of the Wegovy pill as “staggering” and said the company is among the largest providers helping patients access the product. Dudum also said the company has partnered with Novo Nordisk in international markets, including Germany and the U.K
